Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline Review, H1 2018

Publisher Name :
Date: 12-Jun-2018
No. of pages: 67
Inquire Before Buying

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline Review, H1 2018, provides an overview of the Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders) pipeline landscape.

Fibrodysplasia ossificans progressiva (FOP) is a disorder in which muscle tissue and connective tissue such as tendons and ligaments are gradually replaced by bone (ossified), forming bone outside that constrains movement. Symptoms swellings in fibrous tissue, pain, fever, muscle ossification and restricted movement of joints. Treatment includes surgery and medications to help relieve symptoms of FOP, such as pain and inflammation.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders).

- The pipeline guide reviews pipeline therapeutics for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline Review, H1 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Overview
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Companies Involved in Therapeutics Development
AstraZeneca Plc
BioCryst Pharmaceuticals Inc
Blueprint Medicines Corp
Clementia Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
La Jolla Pharmaceutical Company
Oncodesign SA
Pfizer Inc
Regeneron Pharmaceuticals Inc
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Drug Profiles
Antibody to Antagonize ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BCX-9250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BCX-9499 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLU-782 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dipyridamole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Fibrodysplasia Ossificans Progressiva - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
palovarotene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REGN-2477 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REGN-2477 + trevogrumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
saracatinib difumarate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sirolimus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 1 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 2 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Activin Receptor-Like Kinase 2 for fibrodysplasia ossificans progressiva - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Dormant Projects
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Product Development Milestones
Featured News & Press Releases
May 23, 2018: Clementia Reports Positive Phase 2 Part B Data Showing Treatment with Palovarotene Significantly Reduces New Bone Growth in Patients with FOP
Jan 05, 2018: BioCryst Advancing Potential Treatment for Rare and Severely Debilitating Fibrodysplasia Ossificans Progressiva
Jan 05, 2018: BioCryst Provides Update on Drug Candidate BCX9499
Dec 12, 2017: Clementia Initiates Pivotal Phase 3 MOVE Trial for Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva
Aug 31, 2017: Clementia Announces Data Presentations at Upcoming Medical Conferences in September
Jun 05, 2017: Clementia Pharmaceuticals to Host Symposium at the 8th International Conference on Children's Bone Health
Mar 28, 2017: Phase 2 Part A Open Label Extension Trial of Palovarotene for Treatment of Patients with Fibrodysplasia Ossificans Progressiva Continues Positive Trends
Nov 18, 2016: Clementia Clinical Program: Necker Begins Enrolling Patients in Palovarotene 2B Extension Study
Nov 18, 2016: Clementia Clinical Program: Queensland University of Technology (QUT) Institute of Health and Biomedical Innovation (IHBI) Begins Enrolling Patients in Palovarotene 2B Extension Study
Nov 14, 2016: Clementia Clinical Program: Clinical Trial Site for Palovarotene Study Opened in Argentina
Oct 14, 2016: Clementia Announces Top-line Results from Phase 2 Trial of Palovarotene for Treatment of Patients with Fibrodysplasia Ossificans Progressiva
Aug 08, 2016: Clementia Clinical Program: Opportunity for New Adult and Older Adolescent Subjects to Enroll in Palovarotene Study
Jun 13, 2016: Clementia Clinical Program: Next Step in Clementia's Clinical Program for Fibrodysplasia Ossificans Progressiva (FOP)
Apr 23, 2016: Clementia Pharmaceuticals Joins Global FOP Community in Recognizing Fibrodysplasia Ossificans Progressiva (FOP) Awareness Day
Dec 09, 2015: Clementia Clinical Program: Clementia Natural History Study and Phase 2 Clinical Trial Enrollment Update
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by AstraZeneca Plc, H1 2018
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by BioCryst Pharmaceuticals Inc, H1 2018
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Blueprint Medicines Corp, H1 2018
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Clementia Pharmaceuticals Inc, H1 2018
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Daiichi Sankyo Co Ltd, H1 2018
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by La Jolla Pharmaceutical Company, H1 2018
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Oncodesign SA, H1 2018
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Pfizer Inc, H1 2018
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Regeneron Pharmaceuticals Inc, H1 2018
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Dormant Projects, H1 2018

List of Figures
Number of Products under Development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
  • Global Shark Liver Oils Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 16-Nov-2018        Price: US 3480 Onwards        Pages: 102
    Shark liver oil is an oil obtained from the livers of sharks. Scope of the Report: Shark liver oi is promoted as a dietary supplement, and additional claims have been made that it can treat other maladies such as cancer, HIV, radiation illness, swine flu and the common cold. The worldwide market for Shark Liver Oils is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new......
  • Global Neurodegenerative Disease Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 16-Nov-2018        Price: US 3480 Onwards        Pages: 120
    Neurodegenerative disease or neurodegeneration refers to the progressive damage or wear and tear of the nerve cells. Neurodegenerative disease causes loss of abilities like decision making and eventually memory loss. Scope of the Report: This report focuses on the Neurodegenerative Disease in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and......
  • Global Microsclerotherapy Treatment Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 16-Nov-2018        Price: US 3480 Onwards        Pages: 123
    The very thin and tiny veins that look like a spider web below the skin is known as spider veins or thread veins. Spider vein are also known as small varicose veins. They are caused because of the malfunctioning of the valves in the veins. The bloods gets backed up in the veins resulting into swelling. Microsclerotherapy is one of the best technique to treat spider veins. It involves injecting a substance called as sclerosant, which destroys the veins over a period of time and makes it disappear......
  • Global Micro-ultrasound Systems Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 16-Nov-2018        Price: US 3480 Onwards        Pages: 108
    Micro-ultrasound is capable of anatomical imaging. Micro-ultrasound systems generate the sound waves from transducers and penetrate the living tissue for getting the image in 2D or 3D. Micro-ultrasound are very useful for studies smaller animal for research purpose as the range of micro-ultrasound is from 15-20 MHz Micro-ultrasound also helps in early detection of tumor in the body ranging from 50 µm or above. Micro-ultrasound has many application which enable the micro-injection of drug, detect......
  • Global Minimally Invasive Neurosurgery Devices Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 16-Nov-2018        Price: US 3480 Onwards        Pages: 124
    Minimally Invasive Neurosurgery is performed to treat disease occurring in various parts of brain, spinal cord or skull base through a small opening. Diseased area may require repair, removal and in the worst cases replacement which is being done through neurosurgery. Neurosurgical device used for the visualization purpose inside the human brain or spinal cord is known as "Endoscope" which is kind of a small microscope inserted through minimal invasion. Scope of the Report:......
  • Global Mobile Endoscopic Workstations Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 16-Nov-2018        Price: US 3480 Onwards        Pages: 116
    The mobile endoscopic workstations is surgical devices which are used for effective endoscopic surgeries. The mobile endoscopic workstations can accommodate all the required endoscopic devices that are used in an endoscopic surgery. Medical endoscopic workstations comprises a number of features which can be upgraded for user safety and comfort. Scope of the Report: This report focuses on the Mobile Endoscopic Workstations in global market, especially in North America, Europ......
  • Global Monoclonal Antibody Therapeutics Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 16-Nov-2018        Price: US 3480 Onwards        Pages: 120
    For transferring the insulin a device is used that is known as insulin patch pump. Owing to the presence of the adhesive, the insulin patch pump gets directly attached to the body. The presence of the adhesive avoids the requirement of the infusion set and tubing for attaching the pump to the body. Scope of the Report: This report focuses on the Monoclonal Antibody Therapeutics in global market, especially in North America, Europe and Asia-Pacific, South America, Middle Eas......
  • Global Monoclonal Antibody Treatment Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 16-Nov-2018        Price: US 3480 Onwards        Pages: 116
    For transferring the insulin a device is used that is known as insulin patch pump. Owing to the presence of the adhesive, the insulin patch pump gets directly attached to the body. The presence of the adhesive avoids the requirement of the infusion set and tubing for attaching the pump to the body. Scope of the Report: This report focuses on the Monoclonal Antibody Treatment in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East a......
  • Global Mycology Immunoassays Testing Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 16-Nov-2018        Price: US 3480 Onwards        Pages: 124
    he frequency of invasive fungal infections has dramatically increased in the recent years and has high mortality and morbidity. Accurate and early diagnosis is very important for the appropriate antifungal therapy. Conventional techniques like microbiology, radiological and histological remain the basis of diagnosis but have limited impact on clinical decision making. There is always a need to characterize fungi accurately and quickly, which can be done by mycology immunoassays test. The fungi a......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs